Prevention and treatment of hypoglycemia
A technology for hypoglycemia and serum, applied in metabolic diseases, peptide/protein components, drug combinations, etc., can solve problems such as weakening counter-regulatory responses and hypoglycemia risk
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment Construction
[0038] A study was initiated under study protocol 1 below under the study name Regenerate-1 (EudraCT number: 2018-001115-73).
[0039] Unexpectedly, it has been found that GABA can reduce the pathologically increased circulating glucagon concentrations present in type 1 diabetic individuals to more normal concentrations. In view of suggestions in the prior art, as suggested (but not shown in WO2019 / 114718) that GABA acutely increases circulating glucagon levels by acting on glutamate receptors, GABA lowers glucagon levels to normal This ability was unexpected.
[0040] Glucagon concentrations are often pathologically increased in individuals with type 1 and type 2 diabetes, so these individuals have little or no ability to further increase glucagon in response to hypoglycemia. It is important to address this defect in counter-regulatory hormone responses (hormones that increase blood sugar) to protect these patients from severe hypoglycemia. The present invention aims to pro...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


